Home » Stocks » NAVB

Navidea Biopharmaceuticals, Inc. (NAVB)

Stock Price: $1.62 USD -0.01 (-0.61%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 46.56M
Revenue (ttm) 915,013
Net Income (ttm) -11.39M
Shares Out 23.90M
EPS (ttm) -0.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $1.62
Previous Close $1.63
Change ($) -0.01
Change (%) -0.61%
Day's Open 1.63
Day's Range 1.60 - 1.69
Day's Volume 173,291
52-Week Range 0.86 - 5.36

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

4 days ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

3 weeks ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

1 month ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

1 month ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

2 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

2 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

2 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

4 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

4 months ago - Business Wire

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

5 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

5 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

6 months ago - Business Wire

Navidea (NAVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

6 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

6 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

7 months ago - Business Wire

Navidea Biopharmaceuticals: Too Many Risks Involved

7 months ago - Seeking Alpha

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

8 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

8 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunothe...

8 months ago - Business Wire

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunothe...

8 months ago - Business Wire

Investors need to pay close attention to Navidea Biopharmaceuticals (NAVB) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

Retail sales surging 18% in May fared well with the markets this morning, but with growing concerns over a Coronavirus resurgence, it's clear that volatility is just around the corner. We've utilized ou...

Other stocks mentioned: ARCB, ECOR, FLNT, GRUB
10 months ago - Forbes

DUBLIN, OH, June 15, 2020 (GLOBE NEWSWIRE) -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic ag...

10 months ago - GlobeNewsWire

  Live Video Moderated Discussion with CEO, Jed Latkin, to be Held on Tuesday, June 16th, at 2:00 PM ET, Immediately Followed by an Interactive Q&A Session

10 months ago - GlobeNewsWire

Many believe that the market does not accurately the current state of our economy. With double-digit unemployment and Q2 earnings expected to disappoint, the stock market is rich with several Top Shorts...

Other stocks mentioned: BLNK, LQDA, SVRA
11 months ago - Forbes

DUBLIN, Ohio, June 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precisi...

11 months ago - GlobeNewsWire

Navidea Biopharmaceuticals Inc. (NYSE: NAVB) shares more than doubled to close out the week after the company provided an update from its midstage study in patients with active rheumatoid arthritis (RA).

11 months ago - 24/7 Wall Street

Shares of Navidea Biopharmaceuticals Inc. NAVB, -1.55% more than doubled in very active premarket trading Friday, after the company provided upbeat data on an ongoing phase 2 trial of its treatment for ...

11 months ago - Market Watch

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Navidea Biopharmaceuticals' (NAVB) CEO Jed Latkin on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

For real-time updates on NAVB, beat the news and login or try Benzinga Pro. Biotechnology company that specializes in precision medicine, Navidea Biopharmaceuticals Inc (NYSE: NAVB) today had a large op...

1 year ago - Benzinga

Navidea Biopharmaceuticals (NAVB) CEO Jed Latkin on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About NAVB

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET... [Read more...]

Industry
Biotechnology
IPO Date
Nov 10, 1992
CEO
Jed Latkin
Employees
13
Stock Exchange
NYSEAMERICAN
Ticker Symbol
NAVB
Full Company Profile

Financial Performance

In 2020, NAVB's revenue was $915,013, an increase of 39.10% compared to the previous year's $657,826. Losses were -$10.72 million, -2.07% less than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for NAVB stock is "Buy." The 12-month stock price forecast is 7.50, which is an increase of 362.96% from the latest price.

Price Target
$7.50
(362.96% upside)
Analyst Consensus: Buy